Sanofi to test cancer-starving compound in China in 2013

HONG KONG Thu May 24, 2012 2:53pm IST

Related Topics

Stocks

   

HONG KONG (Reuters) - Sanofi-Aventis plans to begin testing a novel compound that is designed to starve liver cancer to death in a phase one human clinical trial in China and possibly South Korea in 2013.

The compound, called slit-trap, was developed by its Chinese collaborator, Shanghai Institutes of Biological Sciences, and will soon be ready for a "first-in-man" trial.

"It is now in pre-clinical (stage) and is going into clinic early next year," said chief executive officer Christopher Viehbacher in an interview in Hong Kong.

The personalized therapy is tailored for a certain type of liver cancer patients who have high levels of a protein called slit, which nourishes the tumor and helps it spread to other parts of the body.

"If you block slit, you essentially starve the cancer to death," said Frank Jiang, Sanofi-Aventis vice-president and head of research and development in the Asia Pacific.

The company is working on ways to identify such patients who can best respond to this therapy, he said.

Though rare in the west, liver cancer is serious in Asia due to the prevalence of hepatitis B infection, which is as high as 10 percent in China's population of 1.3 billion people.

Chronic hepatitis B infection can result in liver cirrhosis and liver cancer later in life.

The French drugmaker is uncertain what percentage of liver cancer patients in China may respond to the therapy.

"But in China, even 10 percent of liver cancer patients would be an incredible number," Jiang said.

In China, there are about 350,000 new liver cancer cases each year, or half of the world's total.

China, one of Sanofi's biggest emerging markets, accounts for less than 5 percent of its global sales. But it is growing at a much faster pace than the company's other emerging markets.

"Certainly, in five years time, you will expect China probably will be our number one emerging market," Viehbacher said. "A lot more of the growth in China has been organic."

(Reporting by Tan Ee Lyn and Donny Kwok; Editing by Robert Birsel)

FILED UNDER:

Ebola Crisis

REUTERS SHOWCASE

Exit Polls

Exit Polls

BJP unlikely to form Jammu & Kashmir govt - polls.  Full Article 

Forceful Conversions

Forceful Conversions

BJP distances itself from religious conversions.  Full Article 

Photo

Fund Raising

Flipkart raises $700 million in fresh funding.   Full Article 

Reforms Push

Reforms Push

Modi may order insurance, coal reforms if vote delayed - officials.  Full Article 

Economic Pulse

Economic Pulse

Crank up public spending to revive growth - chief economic adviser.  Full Article 

Reuters Exclusive

Reuters Exclusive

India looks to sway Americans with nuclear power insurance plan  Full Article 

Down Under

Down Under

Magic Johnson inspires Australia to second test win.  Full Article 

Going International

Going International

Bollywood’s Priyanka Chopra sets sights on American TV.  Full Article 

India This Week

India This Week

Some of our best photos from this week.   Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device   Full Coverage